ARDELYX INC. - COMMON STOCK

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

30 1 2025 15:30:00 提供 Nasdaq GlobeNewswire

Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

13 1 2025 07:03:32 提供 Nasdaq GlobeNewswire

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: ARDELYX INC. - COMMON STOCK

18 12 2024 10:19:26 提供 NetDania Notify

Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

20 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx Responds to District Court Decision Granting Motion to Dismiss

08 11 2024 11:31:21 提供 Nasdaq GlobeNewswire

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

05 11 2024 07:00:32 提供 Nasdaq GlobeNewswire

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

31 10 2024 15:02:40 提供 Nasdaq GlobeNewswire

Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting

28 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

24 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

22 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community

21 10 2024 15:05:00 提供 Nasdaq GlobeNewswire

Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

17 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week

15 10 2024 07:00:20 提供 Nasdaq GlobeNewswire

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

09 10 2024 07:05:00 提供 Nasdaq GlobeNewswire

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

08 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

01 8 2024 15:01:02 提供 Nasdaq GlobeNewswire

Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion

31 7 2024 07:02:00 提供 Nasdaq GlobeNewswire

Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

18 7 2024 07:00:00 提供 Nasdaq GlobeNewswire